Valeant Pharmaceuticals International (VRX) : The consensus on Valeant Pharmaceuticals International (VRX) based on 14 analyst recommendation on the company stock is 2.61, which is interpreted as a Hold recommendation. Zacks Investment Research has issued a rank of 3 which endorses a Hold on the stock. However, 4 brokers have a differing view as they consider the stock to be a Strong Buy at current levels. 1 analyst believes that the stock is a Buy, which can produce decent returns in the future. 7 experts consider that the stocks earnings and the quoted price is in harmony, hence, they give it a Hold rating. 2 analyst sees the stock overvalued at current levels and advises a Strong Sell on the stock.
Valeant Pharmaceuticals International (VRX) : Currently there are 11 street experts covering Valeant Pharmaceuticals International (VRX) stock. The most bullish and bearish price target for the stock is $81 and $22 respectively for the short term. The average price target of all the analysts comes to $42. The estimated standard deviation from the target is $15.8.
Company shares have received an average consensus rating of Hold for the current week Also, Major Brokerage house, Morgan Stanley upgrades its ratings on Valeant Pharmaceuticals International (NYSE:VRX). In the latest research report, Morgan Stanley raises the target price from $33 per share to $42 per share. According to the latest information available, the shares are now rated Overweight by the analysts at the agency. Previously, the analysts had a Equal-weight rating on the shares. The rating by the firm was issued on August 17, 2016.
Valeant Pharmaceuticals International (NYSE:VRX): The stock opened at $30.17 and touched an intraday high of $30.7695 on Wednesday. During the day, the stock corrected to an intraday low of $29.92, however, the bulls stepped in and pushed the price higher to close in the green at $30.27 with a gain of 2.71% for the day. The total traded volume for the day was 14,236,056. The stock had closed at $29.47 in the previous trading session.
Valeant Pharmaceuticals International, Inc. is a specialty pharmaceutical and medical device company. The Company is engaged in developing, manufacturing, and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices), which are marketed directly or indirectly in over 100 countries. The Company operates through two segments: developed markets and emerging markets. The Companys developed markets segment consists of sales in the United States of pharmaceutical products, OTC products, and medical device products. The Companys Emerging Markets segment consists of branded generic pharmaceutical products and branded pharmaceuticals, OTC products, and medical device products.